Newly on Gate2Biotech
First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson\'s Disease
22.4.2014 | Newly on Gate2Biotech
DUBLIN, Ireland, April 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the successful start of a Phase 1...
SynBioBeta announces Lean Launch legend Steve Blank and the Silicon Valley Roundtable
15.4.2014 | Newly on Gate2Biotech
London, UK 25 th March 2014 – The SynBioBeta London 2014 Conference announced today an extended program for Wednesday 2 nd April which will begin with a special presentation of The Lean Launchpad for Biotech, presented by the Father of the Lean Launch and Startup Guru Steve Blank and will also include a Silicon Valley Roundtable.. This will be an...
PHARM Connect 2014 - The business summit covering a full industry
11.4.2014 | Newly on Gate2Biotech
If one had to describe PHARM Connect with one thought, it would most likely be the best all round platform for the entire pharmaceutical industry from early stage R&D to the sealed medicine on the shelves.
Sanofi and Regeneron To Present Alirocumab Clinical Data at American College of Cardiology 63 rd Annual Scientific Session
8.4.2014 | Newly on Gate2Biotech
Paris, France and Tarrytown, NY, March 27, 2014 - Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from alirocumab clinical studies will be presented at the American College of Cardiology's 63rd Annual Scientific Session in Washington, D.C. March 29-31. Alirocumab is an...
TauRx Chairman to present at scientific symposium focused on advances in Alzheimer’s treatments
2.4.2014 | Newly on Gate2Biotech
Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13 th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s.
SCOPE-Zhongyu International Environmental Forum: Programme
27.3.2014 | Newly on Gate2Biotech
Presentation and a roundtable discussion on Emerging Issues in the Green Economy with the laureates of the 2013 SCOPE-Zhongyu Environmental Awards for Young Scientists and invited young scientists.
Global business leaders put the spotlight on innovation as the key to success
4.3.2014 | Newly on Gate2Biotech
Event to showcase cutting-edge European innovation projects. Brussels will play host to a stellar gathering of world-class business leaders, entrepreneurs and innovators when the 2nd European Innovation Convention gets under way next week (March 10-11). The Convention will put the spotlight on the crucial role played by innovation in achieving...
SynBioBeta LONDON 2014
13.2.2014 | Newly on Gate2Biotech
The Conference For Synthetic Biology Startups, Industry and Investors. SynBioBeta announced that it will be hosting its second annual conference on 3rd April 2014 at Imperial College London featuring a mix of panel discussions and talks from startups, industry players, investors and partners in the growing synthetic biology ecos...
Nobel Prize winner in Poland! A unique opportunity to meet Ada Yonath in person
26.12.2013 | Newly on Gate2Biotech
Prof. Ada Yonath agreed to visit BioForum 2014 in Łódź, Poland. She will lead the opening of this event by giving the keynote speech. Prof. Yonath is a laureate of a Nobel Prize in Chemistry. She was awarded this prestigious prize in 2009 in recognition of her work related to studies of the structure and function of the ribosome.
No risk, no profit...
11.12.2013 | Newly on Gate2Biotech
In the companies active in the Central and Eastern European life science sector residues a huge R&D potential. Then why CEE region is not one of the world leaders in this area? This potential remains undiscovered and underestimated and the fact of its existence travels very little beyond the region of Central and Eastern Europe. Only a small...
